Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

Giovanna Elisiana CarpagnanoCorrado PelaiaMaria D'AmatoNunzio CrimiNicola ScichiloneGiulia SciosciaOnofrio RestaCecilia CalabreseGirolamo PelaiaCarla Maria Irene QuaratoMaria Pia Foschino Barbaro

Published in: Therapeutic advances in respiratory disease (2021)

Results of our real-life multicentric experience confirms that the shift to mepolizumab could be a good therapeutic strategy in severe eosinophilic allergic asthma not previously controlled by omalizumab. The reviews of this paper are available via the supplemental material section.

Keyphrases

allergic rhinitis
chronic obstructive pulmonary disease
lung function
early onset
systematic review
randomized controlled trial
drug induced
meta analyses